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Previous studies of nitrostyrene compounds have shown that they possess
considerable antimicrobial activity against pathogenic fungi (1, 2, 3). The success
of these in vitro tests suggested that the in vivo activity be examined in the hope
of finding drugs of value for therapy of mycotic infection.
There does not appear to be much information in the literature dealing with
the effects of nitrostyrenes on higher animals. Other investigators who have
studied the antimicrobial activity of these or of related compounds have noted
that j3-nitrostyrene is a sternutator for man and that this physiological effect is
not necessarily correlated with antifungal activity (4). In a study of the anti-
bacterial properties of some arylnitroalkenes (5), it was shown that mice could
survive $-nitrostyrene in a dose of 80—hO mg/kilo when the compound was
dissolved in propylene glycol and injected intravenously.
The present report deals with experiments designed to show whether certain
nitrostyrene compounds were able to protect mice against deep-seated fungous
infections. LD50 values for acute toxicity of these compounds in mice are included.
MATERIALS AND METHODS
Two compounds were selected from those used in the in vitro tests (1, 2):
3-methyl-f-nitrostyrene and p-methoxy-3-methyl-/3-nitrostyrene. Since both of
these compounds were relatively water insoluble, it was necessary to prepare
suspensions, either in water or in physiological saline. These suspensions tended
to aggregate spontaneously, and one tenth per cent gelatin was added as a stabi-
lizing agent when aqueous suspensions were used. In other tests, microcrystalline
suspensions in Merck vehicle or solutions in peanut or cottonseed oil were pre-
pared. Both drugs were completely soluble in the two oil vehicles at all concentra-
tions used.
Four pathogenic fungi were selected for the evaluation of the nitrostyrene
derivatives in mice. A strain of Blastomyces dermatitidis, BD-16, was kindly fur-
nished by Miss Charlotte Campbell of the Army Medical Service Graduate
School. The strain of Histo plasma capsulatum, designated HC-9, was also fur-
nished by Miss Campbell. The culture of Cry ptococcus neoformans, was furnished
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by Dr. Chester Emmons of the National Institutes of Health. Cultures of Can-
dida albicans and Trichophyton mentagrophytes used in these studies were both
isolated from patients seen in the Department of Dermatology. Organisms were
routinely grown on a medium consisting of 1 per cent neopeptone, 2 per cent
dextrose, and water. This medium was adjusted to pH 7 and used both in the
liquid form and as an agar slant. In certain instances Sabouraud's dextrose agar
was also employed. Three-day broth cultures of B. dermatitis and H. capsulatum
were used and these two species were grown in the yeast phase at 37°C on a
rotary action shaking machine. C. neoformans and C. albicans were grown with
constant agitation at room temperature for 24 hours.
The experimental hot chosen for all of the in vivo protection experiments was
the albino mouse. For experiments in which challenge was made intraperi-
toneally, three-week mice of the NIH (National Institutes of Health) strain was
used. For all other experiments, mice used were of the Swiss Albino strain ob-
tained from the Roscoe B. Jackson Memorial Laboratory. These mice ranged in
age from five to six weeks.
On the basis of in vitro results, several compounds were selected for in vivo
screening. However, of these, only $-methyl-9-nitrostyrene and p-methoxy-$-
methyl-3-nitrostyrene gave promising LD50 values in acute toxicity tests. Each
drug was subjected to preliminary acute toxicity tests in white mice by giving
an arbitrarily selected series of dosage levels by the subcutaneous or intraperi-
toneal route. The animals were observed at hourly intervals for the first four hours
post-inoculation and daily, thereafter, for a minimum of seven days. Cumulative
mortalities were determined by the Reed and Muench method and the final LD50
value was expressed in terms of milligrams of drug per kilogram of body weight.
In order to demonstrate blood levels, the drugs were injected into mice, by
intravenous, intraperitoneal, oral, or subcutaneous routes. Cardiac blood was
removed at intervals and assayed for antifungal activity by the agar diffusion
plate method using C. neoformans or T. mentagrophytes as test organisms.
The ability of the two nitrostyrene compounds to protect mice against infec-
tion with pathogenic fungi was tested in a variety of ways. In some experiments,
aqueous gelatin suspensions of the nitrostyrene compound were mixed with the
organism in vitro and the mixture allowed to incubate at room temperature for
one hour before injection. Following this the mixture of drug and yeast cells was
injected into mice intravenously. In other experiments the yeast cells were given
intravenously and the drug followed by the same route 24 hours later. In these
experiments, the drug was suspended in 0.1 per cent gelatin-saline solution.
In those instances where the drug was dissolved in oil, the oil solutions were
administered by the subcutaneous route, either one hour or 24 hours following
the intravenous administration of yeast cells. In some experiments, the organisms
were suspended in 5 per cent hog gastric mucin and the mixture injected in-
traperitoneally. The nitrostyrene compound, suspended in gelatin solution, was
given 24 hours later. In a few experiments, repeated injections of the drug were
given at various intervals post-infection in order to ascertain whether more
complete protection might be obtained by this method. Mice were observed for a
21-day period following the challenge dose.
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RESULTS
Acute toxicity tests were performed in mice three weeks old. The LD50 values
for methyl-3-nitrostyrene given intraperitoneally were 184 mg/kg of body weight
for the drug suspended in gelatin solution and 160 mg/kg using a suspension in
5 per cent gastric mucin. When peanut oil solutions were injected subcutaneously
the average LD50 value was 467 mg/kg. In the case of p-methoxy-3-methy1-f3-
nitrostyrene, the LD50 values were, in the order given above, 430, 218 and 728
mg/kg of body weight. It is interesting that gastric mucin increased the toxicity
significantly.
Attempts were made to demonstrate blood levels in mice after injection of the
two compounds. Varying amounts were injected by the intravenous, intraperi-
toneal, subcutaneous and oral routes and blood was removed at intervals for
testing. Assay by the agar diffusion plate technic using C. neoformans or T.
mentagrophytes failed to reveal any detectable activity.
The ability of the two nitrostyrene compounds to protect mice against infec-
tion was tested in several ways. The results obtained by incubating p-methoxy-
3-methyl-j3-nitrostyrene with C. neoformans for one hour at room temperature
before injection intravenously into mice may be seen in Table I. The test dose
of Cryptococcus was held constant at 10. One group of mice received 1.0 mg
of the drug, another group received 0.01 mg and a third control group received
none of the nitrostyrene derivative. A parallel experiment was set up using normal
rabbit serum as a diluent instead of physiological saline solution. This was done
in order to ascertain whether components of normal rabbit serum had the ability
to inactivate the drug. Mice were observed for a 21-day period before drawing
the test to a conclusion. It will be seen from the table that significant protection
was obtained with either 0.01 or 1.0 mg of the drug as contrasted to the control
group. Results of experiments in which saline and normal rabbit serum were
used as diluents were comparable. This would seem to indicate that normal rab-
bit serum does not have the ability to inactivate or bind this nitrostyrene com-
pound.
Since the results in the preceding table showed promise, an experiment was
designed to show whether it was possible to protect mice with an injection of
p-methoxy-3-methyl-3-nitrostyrene administered 24 hours after the challenge
dose of organisms. The results of such a study may be seen in Table II. As in
TABLE I









* In vitro incubation for 1 hour at room temperature before injection. Each mouse re-
ceived 10 Cryptocoecus cells.
t Deaths/Totals.
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TABLE II
The effect of intravenous -p-Methoxy--methyl-i3-nitrostyrene on the survival of mice infected
with Cryptococcus neoformans
Initial Injection p-methoxy--methy1-5-nitrostyrene (rug)
1.0 0.01 0
Saline




Both injections were given intravenously with the drug following initial injection after
24 hours. The drug was suspended in 0.1% gelatin solution.
TABLE III
The effect of peanut oil solutions of i3-Methyl-3-nitrostyrene and p-Methoxy-13-methyl-$-






























Cells of C. neoformans, were injected intravenously and the drugs dissolved in oil were
injected subcutaneously 24 hours later.
the preceding experiment, a constant challenge dose of 1O cryptococci was used.
It is obvious from the data that no protection was observed with either level of
drug. In order to determine whether a peanut oil solution of the compound given
subcutaneously might confer more protection because of the increased time
required for absorption, an experiment was set up as shown in Table III. Some-
what higher doses of p-methoxy-3-methyl-9-nitrostyrene were used in this
instance, the larger quantity (5.5 mg) being the approximately LD10. It should
be pointed out that in this case the drug was administered by a different route and
in a different vehicle. Another nitrostyrene compound, 3-methyl-3-nitrostyrene,
was also included in the test. Three different concentrations of C. neoformans
were employed. It will be seen from the table that no degree of protection was
obtained, regardless of the cell concentration or the amount of drug used. Other
experiments were conducted using C. neoformans as the test organism, and em-
ploying various routes of inoculation, both of the compounds and of the test
organism. In some experiments repeated doses of the compounds were given at
various intervals. In no case, however, was any degree of protection observed
except in experiments of the type described in Table I. Procedures similar to
those described for C. neoformans were used in testing the ability of the two
NITROSTYRENES AS ANTIFUNGAL AGENTS 47
nitrostyrenes to protect mice against experimental infections with H. capsulatum,
B. dermatitidis and C. alb'icans. Injections were made by subcutaneous, intra-
venous or intraperitoneal routes. In no case was any significant protection ob-
tained except in one experiment where C. albicans was incubated with the drug
in vitro before intravenous injection. This assay was similar to the one shown
in Table I.
DISCUSSION
The experiments presented in this report have shown that it is possible to
protect mice against infection with C. neoformans and C. albicans by a prelimi-
nary in vitro treatment of the yeast suspension with p-methoxy-j3-methyl-3-
nitrostyrene. These observations are in confirmation of the in vitro results ob-
tained earlier. Additional experiments designed to show whether it was possible
to give an initial challenge dose of the pathogenic fungus and to follow this with
injectionsof the nitrostyrene compounds have yielded disappointing results. In no
case was any significant degree of protection obtained when the injection of the
nitrostyrene compound followed the injection of the fungus. The use of multiple
injections of the drug at 24 hour intervals or at weekly intervals was also found
to yield negative results. On the basis of these experiments as well as other
studies which revealed reduction of the in vitro antifungal activity of the com-
pounds upon addition of whole blood and the failure to demonstrate blood levels
in mice and rabbits, it would seem likely that the nitrostyrene compounds are
being inactivated by some component of the blood or tissues. The results of the
experiments reported here suggest that serum does not inactivate the compounds.
However, other components of the blood, perhaps the erythrocytes or some
component of the erythrocyte, are capable of binding or inactivating these drugs.
Since the in vitro studies have shown considerable promise it would seem that
further studies designed to ascertain how the nitrostyrene compounds are
inactivated in the body might be in order. At any rate, the use of such compounds
at the present time for therapy of deep-seated fungous infections does not seem
to be promising. This does not exclude, however, the use of the nitrostyrenes for
therapy of candidiasis and other conditions were topical application can be
resorted to. The use of p-methoxy-3-methy1-j3-nitrostyrene for topical therapy
of candidiasis will be reported elsewhere.
SUMMARY
The compounds p-methoxy-$-methyl-3-nitrostyrene and 3-methy1-3-nitro-
styrene were tested for their ability to protect mice against experimental infec-
tions with C. neoformans, C. albicans, H. capsulatum and B. dermatitidis. It was
possible to prevent infection in some mice by incubating C. neoformans or C.
albicans with the nitrostyrene for a short period in vitro before the mixture was
inoculated into the animals. When the nitrostyrene was given after the challenge
dose of fungi, however, there was no appreciable difference between treated and
control groups.
No detectable blood levels were observed in rabbits and mice inoculated with
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the nitrostyrene compounds. Although rabbit serum does not interfere with the
antifungal activity of these compounds, they are inactivated by a component
of whole blood.
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